

The background of the slide features a close-up of a person wearing a blue surgical mask. Overlaid on the mask are several digital and technical elements: a circular gauge with multiple concentric rings and numerical markings, and various floating numbers in green and yellow. The overall aesthetic is high-tech and medical.

# **Westwicke/ICR Conference 2021**

*Anthony Fernando, President & CEO*  
*Shameze Rampertab, CFO*

January 14, 2021

# FORWARD LOOKING STATEMENTS



*This presentation includes statements relating to the Senhance Surgical System's market development and a general corporate update. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, whether the market development activities related to the Senhance Surgical System will be successful, the pace of adoption of our products by surgeons, the success and market opportunity of our products, the impact on the ongoing pandemic on our business and our customers, our current cash reach, the effect on our business on existing and new regulatory requirements and other economic and competitive factors and whether we will be able to execute upon our corporate objectives. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the origination date of this presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.*

# OUR STRATEGIC INTENT

At TransEnterix, we believe in digitizing the interface between the surgeon and patient in laparoscopy to increase control and reduce surgical variability for improved patient outcomes in today's value-based healthcare environment.

# TRANSENERIX (NYSE American:TRXC)

EARLY-COMMERCIAL STAGE COMPANY USHERING IN A NEW ERA OF  
MINIMALLY INVASIVE SURGERY



Senhance®



- **Senhance Surgical Robotic System** – the first and only **Digital Laparoscopy** platform
- Significant and differentiated addressable market opportunity
- FDA Cleared, CE Marked and Japan PMDA approved
- Building awareness and ramping up clinical adoption
- Well positioned to bring Augmented Intelligence (AI) and Machine Vision to surgery

# COMPANY SNAPSHOT

FIRST NEW ENTRANT IN THE FIELD OF ABDOMINAL SURGICAL  
ROBOTICS IN NEARLY 20 YEARS




Active sites in the  
U.S., E.U. and Asia

4,000+ Surgeries  
Performed, to date

140 global employees


100+  
Surgeon Users





# GLOBAL TRENDS IN ROBOTIC SURGERY

SURGICAL ROBOTICS IS A LARGE AND FAST GROWING MARKET  
AND LAPAROSCOPIC SURGERY IS A GREENFIELD OPPORTUNITY



# VALUE-BASED HEALTHCARE IS FORCING HOSPITALS TO IMPROVE OUTCOMES, EFFICIENCIES, AND TALENT RETENTION

THE PRESSURE AND IMPACT ON SURGEONS ARE INCREASING UNDER  
THE CONSTRAINTS OF VALUE-BASED HEALTHCARE



OR  
Inefficiencies



Surgical  
Variability



Workforce  
Challenges



**Laparoscopy is the most  
widely performed surgical  
technique and carries  
limitations that compound  
these factors and can  
impact clinical outcomes**

*Digital laparoscopy seeks to address these limitations*

# WE ARE UNIQUELY FOCUSED ON DIGITAL LAPAROSCOPY



AN OPPORTUNITY AND NEED TO ADD TO THE WAYS SURGICAL ROBOTICS CREATES VALUE



## Senhance



## Da Vinci

	Digital Laparoscopy		Robotic Assisted Surgery	
	Feature	Implication	Feature	Implication
Motion	▪ Lap	▪ Familiarity for laparoscopic surgeons	▪ Open	▪ More enabling for non-laparoscopists
Instruments	▪ Fully reusable	▪ Low cost per procedure	▪ Limited Use (10x-15x max)	▪ High cost per procedure
	▪ 5mm and 3mm	▪ Advances MIS benefit	▪ 8mm	▪ Not improving invasiveness over laparoscopy
Additional Features	▪ Haptic feedback	▪ Restores significant sensory input	▪ Wristed instruments	▪ Enabling but higher cost per procedure
	▪ Eye tracking camera control	▪ Novel surgical vision control		
	▪ Open vision system	▪ Leverage best in class visualization technologies		
	▪ Individual boom arms	▪ Full patient access		
	▪ Articulating instruments	▪ Enabling where needed		

*Standard Laparoscopic tools, digital information and decision support tools will be the primary driver of the added value through computer assistance*

*Competitors are following the Da Vinci model*



# SENHANCE SYSTEM ADDRESSES KEY CHALLENGES FACING HOSPITALS AND LAPAROSCOPIC SURGEONS

## BUILDING THE BRIDGE FROM LAPAROSCOPY TO ROBOTICS



**First** robotic system with *Augmented Intelligence (AI) and Machine Vision Capabilities*


**First** robotic system to *offer the security of haptic feedback*

**First** robotic system to *offer simultaneous surgeon-controlled visualization*

**86** different types of *procedure/technique surgeries performed*

New standard in minimally *invasive surgery with **3mm** instruments*

Developed broad instrument *portfolio with **70** instruments in the catalog*




# STRONG, BROAD-BASED CLINICAL PERFORMANCE




SENHANCE DEMONSTRATING STRONG CLINICAL PERFORMANCE  
ACROSS THE THREE MAJOR GEOGRAPHIES

## GLOBAL CLINICAL CASE VOLUME TREND



Strong clinical case performance in 2019  
Strong momentum in Q1 2020 dampened by COVID

## 2019/2020 CASE MIX




Adoption across multiple specialty areas,  
demonstrating broader applicability and adoption


\* TransEnterix Estimates and YTD Actual

# DIGITAL LAPAROSCOPY PLATFORM – MORE THAN THE ROBOT

OUR VISION FOR DIGITAL LAPAROSCOPY GOES BEYOND THE ROBOT




**ROBOTIC  
MANIPULATION**




**OPEN PLATFORM  
ARCHITECTURE**




**INTELLIGENT  
SCENE COGNITION**



**AUGMENTED  
INTELLIGENCE**



**CONNECTIVITY**



**OPERATING ROOM  
WORKFLOW**

# THE FIRST MACHINE VISION SYSTEM IN ROBOTIC SURGERY

LEADING THE WAY IN AUGMENTED INTELLIGENCE AND MACHINE VISION IN SURGERY


## SENHANCE INTELLIGENT SURGICAL UNIT (ISU)




FDA 510(k) Approved  
in March 2020




In Clinical use in  
the US




## DEFECT IDENTIFICATION AND SIZING



## 3D POINT TO POINT MEASUREMENT



## CRITICAL STRUCTURE IDENTIFICATION



FUTURE FEATURE  
ADDITIONS

## Key Operational Accomplishments

---

# 2020 OPERATIONAL HIGHLIGHTS

## SIGNIFICANT OPERATIONAL PROGRESS IN 2020

- Ten Senhance lease agreements signed, 9 clinical programs initiated and completed ~1,450+ cases
- Received FDA clearance and completed first surgical procedures using Augmented Intelligence(AI) and machine vision system, Intelligent Surgical Unit (ISU)
- Received CE Mark and completed first surgical procedures for pediatric use of Senhance with 3 mm instruments in Europe
- Received Russia Regulatory Approval for the Senhance system
- Made FDA 510(k) submission for General Surgery indication expansion
- Established Asia Pacific Training Center at Saitama Medical University International Medical Center in Japan





# 2020 FINANCIALS (UNAUDITED)

A vertical timeline graphic consisting of a thin blue line with two white circles at the top and bottom, and a small tick mark at the very top.

2020 Revenue ~ \$3.0 - \$3.2 million

December 31, 2020 Balance Sheet Highlights

- Cash & Restricted Cash ~ \$17.5 million
- Proforma Cash & Restricted Cash ~84.1 million\*
- Debt – None
- Cash Runway – into Q4 2022

\* The Company closed a Registered Direct Offering for gross proceeds of \$31.25 million and net proceeds of \$28.7 million on January 14, 2021, received proceeds of \$10.6 million on warrant exercises from January 1-12, 2021, and sold shares on the ATM for proceeds of \$27.3 million from January 1-12, 2021

# UPCOMING MILESTONES SUPPORT OPERATIONAL GROWTH

## REGULATORY SUCCESS AND PEER REVIEWED PUBLICATIONS



### Regulatory Milestones (1H)

- Receive CE Mark for ISU in Europe
- Receive FDA 510(k) for General Surgery indication expansion
- File FDA 510(k) for next generation ISU
- File FDA 510(k) for articulating instruments



### Peer Reviewed Publications (1H)

- Health-economic studies of Senhance, laparoscopy and robotics
- Clinical performance
- Operating room efficiency and surgeon ergonomics



Continued momentum and penetration of ISU and usage of Augmented Intelligence and Machine Vision technology in the US, EU and Asia



Further expansion of Pediatrics usage in Europe





SenhanceSurgery

WHEN YOU **DIGITIZE THE  
INTERFACE** BETWEEN THE  
SURGEON AND THE PATIENT,  
SURGERY BECOMES **SAFER  
AND MORE PREDICTABLE**



